HEALTH PLAN POLICY

Policy Title: Spinal Muscular Atrophy - Gene Therapy
Policy Number: MUM67
Revision: New

Department: Medical Management
Sub-Department: Utilization Management

Applies to Product Lines:
- [ ] Medicaid
- [ ] Children’s Health Insurance Plan
- [x] Health Insurance Exchange
- [x] Medicare
- [ ] USFHP
- [x] Commercial Insured
- [ ] Non Insured Business

Origination/Effective Date: 10/09/2019
Reviewed Date(s):
Revision Date(s):

SCOPE:

This document addresses gene therapy for SMA. This disease is very rare and often fatal. It is most common in very young children less than 6 months of age. Currently there are 2 very new pharmacologic agents approved by the FDA including Zolgensma in 2019 for SMA Type 1 and Spinraza in 2016 for SMA Type 2.

DEFINITIONS AND ACRONYM:

- Spinal Muscular Atrophy (SMA)
- Werdig Hoffman Disease – Another Name for SMA Type 1

POLICY: Pharmacologic treatment for SMA is medically necessary under the following provisions:

1) Genetically confirmed diagnosis of SMA
2) Age less than 6 months
3) No use of ventilator support equipment exceeding 16 hours per day
4) No co morbidities including infection, organ failure of heart, liver or kidneys

Rationale:

SMA is a neuromuscular disease of the spine and brainstem. Muscle weakness and atrophy occur especially in the mouth, throat and respiratory capacity. SMA is the most common genetic cause of childhood death.

The incidence of SMA is 1 in 10,000 births. Average life span is about 7.5 months. The pattern of inheritance is autosomal recessive resulting in the disease’s rarity given that each parent must provide a defective gene on their respective Chromosomes #5.

REFERENCES:

- International Consensus Statement -Wang 2007 – Standards of Care for SMA
- Parente 2018 – Statistical Analysis of SMA - Incidence
HEALTH PLAN POLICY

<table>
<thead>
<tr>
<th>Policy Title: Spinal Muscular Atrophy – Gene Therapy</th>
<th>Policy Number: MUM67</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revision: New</td>
<td></td>
</tr>
</tbody>
</table>

- Verhaart 2017 - Statistical Analysis of SMA - Incidence
- Farrar 2013 - Statistical Analysis of SMA – Age as a Predictor of Death

RELATED DOCUMENTS:

None

---

Nancy Herstmann  
Chief Executive Officer Health Plans  
10/21/19  
Date

David Engleking, M.D.  
Medical Director  
10/5/19  
Date

---

REVISION HISTORY:

<table>
<thead>
<tr>
<th>Revision</th>
<th>Date</th>
<th>Description of Change</th>
<th>Committee</th>
</tr>
</thead>
<tbody>
<tr>
<td>New</td>
<td>10/09/2019</td>
<td>Initial release.</td>
<td>Executive Leadership</td>
</tr>
</tbody>
</table>